Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > COMMENTARY
COMMENTARY
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (3)
July 4, 2005
- Former Reviewers' Interviews Make OPIR Report Exciting
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (2)
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (1)
June 20, 2005
- Special Contribution
May 16, 2005
- Japan's Most Admired Pharma Companies P. Reed Maurer President, NPP
April 18, 2005
- PRTM Shows Results of Investigational Drug Survey
March 14, 2005
- ＜Special Comtribution＞
March 7, 2005
- ＜Special Comtribution＞
March 7, 2005
- JPMA Update (12)
November 22, 2004
- JPMA Pudate(11)
November 15, 2004
- JPMA Update (10)
November 8, 2004
- JPMA Update (9)
November 1, 2004
- JPMA Update (8)
October 25, 2004
- JPMA Update (7)
October 18, 2004
- JPMA Update (6)
October 11, 2004
- ＜Special Contribution＞
October 4, 2004
- JPMA Update (5)
October 4, 2004
- JPMA Update(4)
September 27, 2004
- JPMA Update (3)
September 20, 2004
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…